DOCSLIB.ORG

Pharmacy Laws of North Carolina

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

PHARMACY LAWS OF NORTH CAROLINA This compilation of some of the Pharmacy Laws of North Carolina is provided by the Board of Pharmacy for the convenience of its licensees and the public. It is not guaranteed to be a complete collection of all of the relevant laws, nor to be correct or updated. For complete guidance, you must refer to the official North Carolina General Statutes and Session Laws or consult an attorney. Pharmacy Practice Act, N.C. Gen. Stat. §§ 90-85.2 to 90-85.44 .................................................................................. 1 Other Selected Provisions of Chapter 90, Medicine and Allied Occupations Practice of Medicine, N.C. Gen. Stat. §§ 90-1 to 90-21 (selected provisions) ............................................. 28 Treatment of Minors N.C. Gen. Stat. §§ 90-21.1 to 90-21.5 (selected provisions) ...................................... 35 Medical Malpractice Actions, N.C. Gen. Stat. §§ 90-21.11 to 90-21.19B (selected provisions) ................. 36 Voluntary Health Care Services Act, N.C. Gen. Stat. §§ 90-21.100 to 21.108 ............................................ 44 Emergency or Disaster Treatment Protection Act, §§ 90-21.130 to 90-21.134 ............................................ 47 Pharmacy Quality Assurance Protection Act, N.C. Gen. Stat. §§ 90-85.45 to 90-85.47 .............................. 49 Pharmacy Audit Rights, N.C. Gen. Stat. §§ 90-85.50 to 90-85.53 ............................................................... 51 North Carolina Controlled Substances Act, N.C. Gen. Stat. §§ 90-86 to 90-113.8 (selected provisions) .... 53 Needle and hypodermic syringe exchange programs authorized; limited immunity N.C. Gen. Stat. § 90-113.27 ..................................................................................................................... 83 Control of Methamphetamine Precursors, N.C. Gen. Stat. §§ 90-113.50 to 90-113.64 (selected provisions) ............................................................................................................................... 84 North Carolina Controlled Substances Reporting System Act, N.C. Gen. Stat. §§ 90-113.70 to 90-113.76 ............................................................................................. 87 Right to Try Act, §§ 90-325 to 90-325.17 (selected provisions) .................................................................. 97 Referral Fees and Payment for Certain Solicitations Prohibited, N.C. Gen. Stat. §§ 90-400 to 90-402 ...... 99 Medical Records, N.C. Gen. Stat. §§ 90-410 to 90-412 ............................................................................... 99 Statewide Health Information Exchange Act, §§ 90-414.1 to 90-414.12 .................................................... 100 Health Care Practitioner Identification, N.C. Gen. Stat. § 90-640 ............................................................. 108 Selected Provisions of Chapter 14, Criminal Law Death by distribution of certain controlled substances; aggravated death by distribution of certain controlled substances; penalties, N.C. Gen. Stat. § 14-18.4 .................................................................. 109 Public officers or employees benefitting from public contracts; exceptions, N.C. Gen. Stat. § 14-234 ....................................................................................................................... 109 North Carolina Pharmacy Law – Effective September 1, 2021 i Selected Provisions of Chapter 15, Criminal Procedure Execution, N.C. Gen. Stat. §§ 15-187 to 15-195 (selected provisions) ..................................................... 112 Selected Provisions of Chapter 58, Insurance Definitions, N.C. Gen. Stat. § 58-1-5 ......................................................................................................... 113 False statement to procure or deny benefit of insurance policy or certificate, N.C. Gen. Stat. § 58-2-161 .................................................................................................................... 113 General Regulations for Insurance, N.C. Gen. Stat. §§ 58-3-1 to 58-3-290 (selected provisions) ............. 114 Right to choose services of certain providers, N.C. Gen. Stat. § 58-50-30 ................................................. 116 Pharmacy of choice, N.C. Gen. Stat. § 58-51-37 ....................................................................................... 117 Pharmacy Benefits Management, N.C. Gen. Stat. §§ 58-56A-1 to 58-56A-10 .......................................... 119 Selected Provisions of Chapter 75, Monopolies, Trusts and Consumer Protection Telephone Solicitations, N.C. Gen. Stat. §§ 75-100 to 75-105 (selected provisions) ................................ 121 Selected Provisions of Chapter 93B, Occupational Licensing Boards, N.C. Gen. Stat. §§ 93B-1 to 93B-16 .......... 124 Selected Provisions of Chapter 99B, Products Liability ........................................................................................... 133 Selected Provisions of Chapter 106, Agriculture Food, Drugs and Cosmetics, N.C. Gen. Stat. §§ 106-120 to 106-145 (selected provisions) ...................... 136 Wholesale Prescription Drug Distributors, N.C. Gen. Stat. §§ 106-145.1 to 106-145.12 .......................... 151 Selected Provisions of Chapter 115C, Elementary and Secondary Education Charter Schools, N.C. Gen. Stat. §§ 115C-218 to 115C-218.115 (selected provisions) ............................. 157 Optional Programs, N.C. Gen. Stat. §§ 115C-230 to 115C-238.73 (selected provisions) .......................... 157 Special Medical Needs of Students, N.C. Gen. Stat. §§ 115C-375.1 to 115C-375.5 (selected provisions) ............................................................................................................................. 158 Selected Provisions of Chapter 130A, Public Health Definitions, N.C. Gen. Stat. § 130A-2 ........................................................................................................ 160 Commission for Public Health – Members; selection; quorum; compensation, N.C. Gen. Stat. § 130A-30 .................................................................................................................... 160 Maternal Mortality Review Committee; membership, compensation, N.C. Gen. Stat. § 130A-33.60 ....... 160 Local Administration, N.C. Gen. Stat. §§ 130A-34 to 130A-85 (selected provisions) .............................. 161 Communicable Diseases, Immunization, N.C. Gen. Stat. §§ 130A-152 to 130A-158 (selected provisions) ......................................................... 163 North Carolina Pharmacy Law – Effective September 1, 2021 ii Selected Provisions of Chapter 131E, Health Care Facilities and Services Hospital Licensure Act, N.C. Gen. Stat. §§ 131E-75 to 131E-99 (selected provisions) ............................ 166 Health Care Facility Licensure Act, Nursing Home Patients’ Bill of Rights, N.C. Gen. Stat. §§ 131E-115 to 131E-131 (selected provisions) .......................................................... 167 Selected Provisions of Chapter 143B, Executive Organization Act of 1973 The Justus-Warren Heart Disease and Stroke Prevention Task Force, N.C. Gen. Stat. § 143B-216.60 .... 171 Selected Provisions of Chapter 150B, Administrative Procedure Act General Provisions, N.C. Gen. Stat. §§ 150B-1 to 150B-4 ........................................................................ 173 Rules, N.C. Gen. Stat. §§ 150B-18 to 150B-21.28 (selected provisions) ................................................... 175 Other Administrative Hearings, N.C. Gen. Stat. §§ 150B-38 to 150B-42 ................................................. 189 Judicial Review, N.C. Gen. Stat. §§ 150B-43 to 150B-52 ......................................................................... 192 Selected Provisions of Chapter 153A, Counties Authority of boards of commissions in certain counties over commissions, boards, agencies, etc. N.C. Gen. Stat. §§ 153A-77 ................................................................................................................... 195 North Carolina Pharmacy Law – Effective September 1, 2021 iii CHAPTER 90 MEDICINE AND ALLIED OCCUPATIONS Article 4A. North Carolina Pharmacy Practice Act. Part 1. North Carolina Pharmacy Practice Act. § 90-85.2. Legislative findings. The General Assembly of North Carolina finds that mandatory licensure of all who engage in the practice of pharmacy is necessary to insure minimum standards of competency and to protect the public from those who might otherwise present a danger to the public health, safety and welfare. § 90-85.3. Definitions. (Version effective until October 1, 2021) (a) "Administer" means the direct application of a drug to the body of a patient by injection, inhalation, ingestion or other means. (b) "Board" means the North Carolina Board of Pharmacy. (b1) "Certified pharmacy technician" means a pharmacy technician who (i) has passed a nationally recognized pharmacy technician certification board examination, or its equivalent, that has been approved by the Board and (ii) obtains and maintains certification from a nationally recognized pharmacy technician certification board that has been approved by the Board. (b2) "Clinical pharmacist practitioner" means a licensed pharmacist who meets the guidelines and criteria for such title established by the joint subcommittee of the North Carolina Medical Board and the North Carolina Board of Pharmacy and is authorized to enter into drug therapy management agreements with physicians in
Recommended publications
  • Minnesota Statutes 1979 Supplement

    Minnesota Statutes 1979 Supplement

    MINNESOTA STATUTES 1979 SUPPLEMENT 152.01 PROHIBITED DRUGS CHAPTER 152. PROHIBITED DRUGS Sec. 152.01 Definitions. 152.02 Schedules of controlled substances; admin­ istration of chapter. 152.01 Definitions. [For text of subds 1 to 8, see M.S.1978] Subd. 9. Marijuana. "Marijuana" means all parts of the plant of any species of the genus Cannabis, including all agronomical varieties, whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin, but shall not include the mature stalks of such plant, fiber from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mix­ ture, or preparation of such mature stalks, except the resin extracted therefrom, fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination. [For text of subds 10 to 17, see M.S.1978] [ 1979 c 157 s 1 ] 152.02 Schedules of controlled substances; administration of chapter. [For text of subd 1, see M.S.1978) Subd. 2. The following items are listed in Schedule I: (1) Any of the following substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the exis­ tence of such isomers, esters, ethers and salts is possible within the specific chemical des­ ignation: Acetylmethadol; Allylprodine; Alphacetylmethadol; Alphameprodine; Alpham- ethadol; Benzethidine; Betacetylmethadol; Betameprodine; Betamethadol; Betaprodine; Clonitazene; Dextromoramide; Dextrorphan; Diampromide; Diethyliambutene; Dime- noxadol; Dimepheptanol; Dimethyliambutene; Dioxaphetyl butyrate; Dipipanone; Ethylmethylthiambutene; Etonitazene; Etoxeridine; Furethidine; Hydroxypethidine; Ke- tobemidone; Levomoramide; Levophenacylmorphan; Morpheridine; Noracymethadol; Norlevorphanol; Normethadone; Norpipanone; Phenadoxone; Phenampromide; Pheno- morphan; Phenoperidine; Piritramide; Proheptazine; Properidine; Racemoramide; Tri­ meperidine.
  • Palliative Care Case of the Month

    Palliative Care Case of the Month

    PALLIATIVE CARE CASE OF THE MONTH “Treating Non-Infectious Diarrhea” by Robert Arnold, MD Volume 19, No. 98 August, 2019 Case 1: Mr. Jones is a 58-year-old man with short gut Three drugs are used because of their ability to slow down the syndrome. Palliative Care was consulted for goals of care, gut, allowing for more time for absorption of intestinal fluids a however quickly it became clear uncontrolled diarrhea was a decrease of diarrhea. The most well-know is loperamide, a larger priority. He said having to change the bag every few hours synthetic opiate which has minimal absorption. The dosing is 4 completely interfered with his living a normal life. He said, “I’d mg after one’s first bowel movement and then 2 mg after every rather die than have all of this diarrhea.” unformed stool, up to 16 mg (in palliative care patients there is some data for use up to 54 mg).9, 10 Loperamide should be Case 2: A 62-year-old woman with non-small cell lung cancer continued for 12 hours after diarrhea is stopped. Adverse effects is receiving immunotherapy. She has done quite well but is include mostly constipation, abdominal cramps, nausea and distressed by her diarrhea. She tried Lomotil and Imodium but rarely CNS effects like fatigue or dizziness. Cases of torsades de neither worked. When seeing her palliative care doctor, she said, pointes and death have been reported with higher than “It isn’t worth treating my cancer if I can’t live a normal life.” 9 recommended doses.
  • Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances 2017

    Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances 2017

    INTERNATIONAL NARCOTICS CONTROL BOARD Precursors and chemicals frequently used in the illicit manufacture of narcotic drugs and psychotropic substances 2017 EMBARGO Observe release date: Not to be published or broadcast before Thursday, 1 March 2018, at 1100 hours (CET) UNITED NATIONS CAUTION Reports published by the International Narcotics Control Board in 2017 The Report of the International Narcotics Control Board for 2017 (E/INCB/2017/1) is supplemented by the following reports: Narcotic Drugs: Estimated World Requirements for 2018—Statistics for 2016 (E/INCB/2017/2) Psychotropic Substances: Statistics for 2016—Assessments of Annual Medical and Scientific Requirements for Substances in Schedules II, III and IV of the Convention on Psychotropic Substances of 1971 (E/INCB/2017/3) Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances: Report of the International Narcotics Control Board for 2017 on the Implementation of Article 12 of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 (E/INCB/2017/4) The updated lists of substances under international control, comprising narcotic drugs, psychotropic substances and substances frequently used in the illicit manufacture of narcotic drugs and psychotropic substances, are contained in the latest editions of the annexes to the statistical forms (“Yellow List”, “Green List” and “Red List”), which are also issued by the Board. Contacting the International Narcotics Control Board The secretariat of the Board may be reached at the following address: Vienna International Centre Room E-1339 P.O. Box 500 1400 Vienna Austria In addition, the following may be used to contact the secretariat: Telephone: (+43-1) 26060 Fax: (+43-1) 26060-5867 or 26060-5868 Email: [email protected] The text of the present report is also available on the website of the Board (www.incb.org).
  • Anti-Diarrheal Activity and Brine Shrimp Lethality Bioassay of Methanolic Extract of Cordyline Fruticosa (L.) A

    Anti-Diarrheal Activity and Brine Shrimp Lethality Bioassay of Methanolic Extract of Cordyline Fruticosa (L.) A

    Naher et al. Clinical Phytoscience (2019) 5:15 https://doi.org/10.1186/s40816-019-0109-z ORIGINAL CONTRIBUTION Open Access Anti-diarrheal activity and brine shrimp lethality bioassay of methanolic extract of Cordyline fruticosa (L.) A. Chev. leaves Sharmin Naher1*, Md. Abdullah Aziz1, Mst. Irin Akter2, S. M. Mushiur Rahman1, Sadiur Rahman Sajon1 and Kishor Mazumder1,3 Abstract Background: Cordyline fruticosa (L.) A. Chev. (Asparagaceae) is a plant which is traditionally used for the treatment of cough, bloody cough, diarrhea, dysentery, high fever, difficulties in urine, bloody urine, small pox, madness, skin eruptions, joint pains, rheumatic bone pains, sore throat, neck pain, bleeding hemorrhoids and inflammation in the digestive tract. Therefore, the present work aims to investigate the antidiarrheal and cytotoxic activities of methanolic extract of Cordyline fruticosa leaves in mice and brine shrimp, respectively. Methods: The effects of the methanol extract of Cordyline fruticosa leaves (MCFL) on castor oil-induced diarrhea, magnesium sulphate induced diarrhea and charcoal meal test in mice were investigated. In addition, brine shrimp lethality bioassay method was used to evaluate cytotoxic activity of MCFL. Results: In castor oil induced diarrheal test, MCFL at the dose of 200, 400 and 800 mg/kg body weight significantly (∗P< 0.05, versus control) and dose-dependently reduced the frequency of diarrhea. The frequency of magnesium sulphate-induced diarrhea was significantly reduced by MCFL at the dose of with 800 mg/kg. In the charcoal meal test, the extract at the dose of 400 and 800 mg/kg body weight significantly (∗P< 0.05) reduced the distance travelled by charcoal along the intestinal tract when compare with control.
  • Federal Register/Vol. 85, No. 36/Monday, February 24, 2020

    Federal Register/Vol. 85, No. 36/Monday, February 24, 2020

    10466 Federal Register / Vol. 85, No. 36 / Monday, February 24, 2020 / Notices Controlled substance Drug code Schedule Alphamethadol ................................................................................................................................................................. 9605 I Benzethidine .................................................................................................................................................................... 9606 I Betacetylmethadol ........................................................................................................................................................... 9607 I Clonitazene ...................................................................................................................................................................... 9612 I Diampromide ................................................................................................................................................................... 9615 I Diethylthiambutene .......................................................................................................................................................... 9616 I Dimethylthiambutene ....................................................................................................................................................... 9619 I Ketobemidone .................................................................................................................................................................
  • Designer Drugs SUBJECT FORENSIC SCIENCE

    Designer Drugs SUBJECT FORENSIC SCIENCE

    SUBJECT FORENSIC SCIENCE Paper No. and Title PAPER No. 9: Drugs of Abuse Module No. and Title MODULE No. 17: Designer Drugs Module Tag FSC_P9_M17 FORENSIC SCIENCE PAPER No. 9: Drugs of Abuse MODULE No. 17: Designer Drugs TABLE OF CONTENTS 1. Learning Outcomes 2. Introduction 3. Forensic Issues 4. Classification of Designer Drugs 5. Some Notable Designer Drugs 6. Forensic Analysis of Designer Drugs 7. Summary FORENSIC SCIENCE PAPER No. 9: Drugs of Abuse MODULE No. 17: Designer Drugs 1. Learning Outcomes After studying this module, you shall be able to know about: The significance of Designer Drugs Classification of Designer Drugs Forensic analysis of Designer Drugs 2. Introduction Over ages, humans fortunately discovered that certain ingested plants were a source of unique satisfying feelings, beyond satiety. Some were mildly affecting (e.g. nicotine, caffeine), others enhanced mood or altered perception, reduced pain, intoxicated, or produced euphoria (e.g. alcohol, marijuana, hallucinogens, opiates, cocaine). In the past two centuries, consumption of these psychoactive substances expanded rapidly. Decontamination of the active chemicals, distribution by manoeuvres for maximum effect and global marketing contributed to this expansion. Modern chemistry has produced a huge range of variations of these plant products, paralleled by an unprecedented level of adverse biological, behavioural, medical and social consequences. Following this phenomenon, Designer drugs are produced to be similar to, but not identical with Psychoactive Drugs that are illegal to possess or sell for human consumption, unless for medical purposes. A recurring threat to public health, the Designer Drug sub-culture has burst out over the past decade.
  • Opioid Powders Page: 1 of 9

    Opioid Powders Page: 1 of 9

    Federal Employee Program® 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.64 Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Analgesics and Anesthetics Original Policy Date: October 20, 2017 Subject: Opioid Powders Page: 1 of 9 Last Review Date: March 13, 2020 Opioid Powders Description Buprenorphine Powder, Butorphanol Powder, Codeine Powder, Hydrocodone Powder, Hydromorphone Powder, Levorphanol Powder, Meperidine Powder, Methadone Powder, Morphine Powder, Oxycodone Powder, Oxymorphone Powder Background Pharmacy compounding is an ancient practice in which pharmacists combine, mix or alter ingredients to create unique medications that meet specific needs of individual patients. Some examples of the need for compounding products would be: the dosage formulation must be changed to allow a person with dysphagia (trouble swallowing) to have a liquid formulation of a commercially available tablet only product, or to obtain the exact strength needed of the active ingredient, to avoid ingredients that a particular patient has an allergy to, or simply to add flavoring to medication to make it more palatable. Buprenorphine, butorphanol, codeine, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, oxycodone, and oxymorphone powders are opioid drugs that are used for pain control. The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines. Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death (1-15). Regulatory Status 5.70.64 Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Analgesics and Anesthetics Original Policy Date: October 20, 2017 Subject: Opioid Powders Page: 2 of 9 FDA-approved indications: 1.
  • 2013 House Judiciary Hb 1070

    2013 House Judiciary Hb 1070

    2013 HOUSE JUDICIARY HB 1070 2013 HOUSE STANDING COMMITTEE MINUTES House Judiciary Committee Prairie Room, State Capitol HB 1070 January 14, 2013 Job #17167 D Conference Committee � · Committee Clerk Signature A-. .;' /) .1� ' I A.J4-��'N'f?4<'71<P2/ I Explanation or reason for introduction of bill/resolution: Relating to the scheduling of controlled substances. Minutes: Chairman Koppelman: Opened the hearing on HB 1070. Mark Hardy, Assistant Executive Director of the NO State Board of Pharmacy: (See testimony #1and 2) He went over these handouts. Rep. Klemin: I don't see an emergency clause in the bill and there is none in the amendment. Did I miss it? Mark Hardy: I want to put an emergency clause on the bill. Rep. Klemin: I think you have to have another section at the end of the bill saying this is an emergency. Rep. Kretschmar: How often do these new drugs come out and should be on it? Mark Hardy: As far as the schedule 1 substances; it is a revolving door and we are always trying to stay in front of what the chemists and what the drug makers are doing. As far as schedule 2 through 5; it is a continuous thing through the DEA. When it becomes a federally controlled substance it takes precedence. Rep. Larson: You have not been aware of the bill I was sponsoring regarding synthetic drugs yet? Mark Hardy: No. The Attorney General briefed me on the Bill #1133. Rep. Larson: The reason for my bill is not get into all of the pharmaceutical names of the chemicals, but anybody that possess or manufacturers a analog in order to try and copy these drugs would be guilty of those offences without having to know the specific chemical compound that might be morphed by unscrupulous people trying to see these products.
  • Table 6.12: Deaths from Poisoning, by Sex and Cause, Scotland, 2016

    Table 6.12: Deaths from Poisoning, by Sex and Cause, Scotland, 2016

    Table 6.12: Deaths from poisoning, by sex and cause, Scotland, 2016 ICD code(s), cause of death and substance(s) 1 Both Males Females ALL DEATHS FROM POISONING 2 1130 766 364 ACCIDENTS 850 607 243 X40 - X49 Accidental poisoning by and exposure to … X40 - Nonopioid analgesics, antipyretics and antirheumatics Paracetamol 2 1 1 Paracetamol, Cocaine, Amphetamine || 1 0 1 X41 - Antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified Alprazolam, MDMA, Cocaine || Cannabis, Alcohol 1 1 0 Alprazolam, Methadone || Pregabalin, Tramadol, Gabapentin, Cannabis 1 1 0 Alprazolam, Morphine, Heroin, Dihydrocodeine, Buprenorphine || Alcohol 1 1 0 Alprazolam, Oxycodone, Alcohol || Paracetamol 1 0 1 Amitriptyline, Cocaine, Etizolam || Paracetamol, Codeine, Hydrocodone, Alcohol 1 1 0 Amitriptyline, Dihydrocodeine || Diazepam, Paracetamol, Verapamil, Alcohol 1 1 0 Amitriptyline, Fluoxetine, Alcohol 1 0 1 Amitriptyline, Methadone, Diazepam || 1 1 0 Amitriptyline, Methadone, Morphine, Etizolam || Gabapentin, Cannabis, Alcohol 1 1 0 Amitriptyline, Venlafaxine 1 0 1 Amphetamine 1 1 0 Amphetamine || 1 1 0 Amphetamine || Alcohol 1 1 0 Amphetamine || Chlorpromazine 1 1 0 Amphetamine || Fluoxetine 1 1 0 Amphetamine, Dihydrocodeine, Alcohol || Procyclidine, Tramadol, Duloxetine, Haloperidol 1 0 1 Amphetamine, MDMA || Diclazepam, Cannabis, Alcohol 1 1 0 Amphetamine, Methadone || 1 1 0 Amphetamine, Oxycodone, Gabapentin, Zopiclone, Diazepam || Paracetamol, Alcohol 1 0 1 Amphetamine, Tramadol || Mirtazapine, Alcohol 1 1 0 Benzodiazepine
  • CONTROLLED SUBSTANCE, DRUG, DEVICE and COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun

    CONTROLLED SUBSTANCE, DRUG, DEVICE and COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun

    CONTROLLED SUBSTANCE, DRUG, DEVICE AND COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun. 23, 2011, P.L. 36, No. 7 Cl. 35 Session of 2011 No. 2011-7 SB 1006 AN ACT Amending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for Schedule I controlled substances. The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows: Section 1. Section 4(1) of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, amended November 24, 1999 (P.L.894, No.55), is amended to read: Section 4. Schedules of Controlled Substances.--The following schedules include the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. (1) Schedule I--In determining that a substance comes within this schedule, the secretary shall find: a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. The following controlled substances are included in this schedule: (i) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation: 1.
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • Us Anti-Doping Agency

    Us Anti-Doping Agency

    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used